Journal of Surgery Concepts & Practice >

2020 , Vol. 25 >Issue 01: 29 - 34

DOI: https://doi.org/10.16139/j.1007-9610.2020.01.007

Experts forum

Occurrence and treatment of hypertension associated with targeted therapy in hepatocellular carcinoma

Expand

Received date: 2019-10-25

  Online published: 2020-02-25

Fold

Cite this article

ZHANG Ti, YANG Xuejiao . Occurrence and treatment of hypertension associated with targeted therapy in hepatocellular carcinoma[J]. Journal of Surgery Concepts & Practice, 2020 , 25(01) : 29 -34 . DOI: 10.16139/j.1007-9610.2020.01.007

References

[1] Greten TF, Lai CW, Li G, et al. Targeted and immune-based therapies for hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2):510-524.
[2] Pan Z, Zhuang J, Ji C, et al. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression[J]. Oncol Lett, 2018, 15(4):4821-4826.
[3] Duffaud F, Sleijfer S, Litiere S, et al. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials[J]. Eur J Cancer, 2015, 51(17):2615-2623.
[4] Gensicka M, Glowacka A, Dzierzbicka K, et al. Inhibitors of angiogenesis in cancer therapy-synthesis and biological activity[J]. Curr Med Chem, 2015, 22(33):3830-3847.
[5] Shigeta K, Datta M, Hato T, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma[J]. Hepatology, 2019,doi: 10.1002/hep.30889.
[6] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
[7] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66.
[8] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
[9] Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1):54-63.
[10] Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase Ⅲ BRISK-FL study[J]. J Clin Oncol, 2013, 31(28):3517-3524.
[11] Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase Ⅲ trial[J]. J Clin Oncol, 2015, 33(2):172-179.
[12] Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase Ⅲ trial[J]. J Clin Oncol, 2013, 31(32):4067-4075.
[13] Cheng AL, Thongprasert S, Lim HY, et al. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma[J]. Hepatology, 2016, 64(3):774-784.
[14] Kang YK, Yau T, Park JW, et al. Randomized phase Ⅱ study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma[J]. Ann Oncol, 2015, 26(12):2457-2463.
[15] Zhu AX, Ancukiewicz M, Supko JG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase Ⅱ study[J]. Clin Cancer Res, 2013, 19(6):1557-1566.
[16] Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2):282-296.
[17] Siegel AB, Cohen EI, Ocean A, et al. Phase Ⅱ trial eva-luating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2008, 26(18):2992-2998.
[18] Azizi M, Chedid A, Oudard S. Home blood-pressure mo-nitoring in patients receiving sunitinib[J]. N Engl J Med, 2008, 358(1):95-97.
[19] Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels[J]. Hypertension, 2010, 56(4):675-681.
[20] Lankhorst S, Baelde HJ, Clahsen-van Groningen MC, et al. Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib[J]. Nephrol Dial Transplant, 2016, 31(6):914-921.
[21] Hamnvik OP, Choueiri TK, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway[J]. Cancer, 2015, 121(2):311-319.
[22] Abdel-Qadir H, Ethier JL, Lee DS, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis[J]. Cancer Treat Rev, 2017, 53:120-127.
[23] Carter JJ, Fretwell LV, Woolard J. Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats[J]. FASEB J, 2017, 31(3):1193-1203.
[24] Mohammadzadeh M, Halabian R, Gharehbaghian A, et al. Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity[J]. Cell Stress Chaperones, 2012, 17(5):553-565.
[25] Verdonk K, Saleh L, Lankhorst S, et al. Association stu-dies suggest a key role for endothelin-1 in the pathogene-sis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression[J]. Hypertension, 2015, 65(6):1316-1323.
[26] de Jesus-Gonzalez N, Robinson E, Moslehi J, et al. Ma-nagement of antiangiogenic therapy-induced hypertension[J]. Hypertension, 2012, 60(3):607-615.
[27] Gennari-Moser C, Khankin EV, Escher G, et al. Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia[J]. Hypertension, 2013, 61(5):1111-1117.
[28] Serne EH, Gans RO ter Maaten JC, et al. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction[J]. Hypertension, 2001, 38(2):238-242.
[29] Wiig H, Schröder A, Neuhofer W, et al. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure[J]. J Clin Invest, 2013, 123(7):2803-2815.
[30] Selvarajah V, Mäki-Petaja KM, Pedro L, et al. Novel mechanism for buffering dietary salt in humans: effects of salt loading on skin sodium, vascular endothelial growth factor C, and blood pressure[J]. Hypertension, 2017, 70(5):930-937.
[31] Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase Ⅱ randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors[J]. J Clin Oncol, 2009, 27(36):6152-6159.
[32] Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2016, 37(36):2768-2801.
[33] Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors[J]. J Natl Cancer Inst, 2010, 102(9):596-604.
[34] Caletti S, Paini A, Coschignano MA, et al. Management of VEGF-Targeted therapy-induced hypertension[J]. Curr Hypertens Rep, 2018, 20(8):68.
[35] Derosa L, Izzedine H, Albiges L, et al. Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma[J]. Oncol Rev, 2016, 10(2):298.
[36] Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients[J]. Ann Oncol, 2009, 20(5):807-815.
[37] Ishikane S, Takahashi-Yanaga F. The role of angiotensin Ⅱ in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis[J]. Biochem Pharmacol, 2018, 151:96-103.
[38] Lankhorst S, Kappers MH, van Esch JH, et al. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study[J]. Hypertension, 2014, 64(6):1282-1289.
[39] Liu Y, Li B, Wang X, et al. Angiotensin-(1-7) suppresses hepatocellular carcinoma growth and angiogenesis via complex interactions of angiotensin Ⅱ type 1 receptor, angiotensin Ⅱ type 2 receptor and mas receptor[J]. Mol Med, 2015, 21:626-636.
[40] Andoh T, Akira A, Saiki I, et al. Bradykinin increases the secretion and expression of endothelin-1 through kinin B2 receptors in melanoma cells[J]. Peptides, 2010, 31(2):238-241.
[41] Pasquier E, Street J, Pouchy C, et al. β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma[J]. Br J Cancer, 2013, 108(12):2485-2494.
[42] Kruzliak P, Novák J, Novák M. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on lon-gacting nitric oxide donors[J]. Am J Hypertens, 2014, 27(1):3-13.
Options
Outlines

/

〈 〉